JP4719144B2 - ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体 - Google Patents

ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体 Download PDF

Info

Publication number
JP4719144B2
JP4719144B2 JP2006505892A JP2006505892A JP4719144B2 JP 4719144 B2 JP4719144 B2 JP 4719144B2 JP 2006505892 A JP2006505892 A JP 2006505892A JP 2006505892 A JP2006505892 A JP 2006505892A JP 4719144 B2 JP4719144 B2 JP 4719144B2
Authority
JP
Japan
Prior art keywords
group
compound
mmol
ethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006505892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006521335A (ja
JP2006521335A5 (https=
Inventor
マシュー リーズ，
アラン ピュロヒット，
マイケル ジョン リード，
サイモン ポール ニューマン，
スリンダー クマール チャンダー，
ファブリス ジョーダン，
バリー ビクター ロイド ポッター，
Original Assignee
ステリックス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0306717A external-priority patent/GB0306717D0/en
Priority claimed from GB0315885A external-priority patent/GB0315885D0/en
Application filed by ステリックス リミテッド filed Critical ステリックス リミテッド
Publication of JP2006521335A publication Critical patent/JP2006521335A/ja
Publication of JP2006521335A5 publication Critical patent/JP2006521335A5/ja
Application granted granted Critical
Publication of JP4719144B2 publication Critical patent/JP4719144B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2006505892A 2003-03-24 2004-02-20 ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体 Expired - Fee Related JP4719144B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0306717.0 2003-03-24
GB0306717A GB0306717D0 (en) 2003-03-24 2003-03-24 Compound
GB0315885.4 2003-07-07
GB0315885A GB0315885D0 (en) 2003-07-07 2003-07-07 Compound
PCT/GB2004/000705 WO2004085459A1 (en) 2003-03-24 2004-02-20 Oestrogen derivatives as inhibitors of steroid sulphatase

Publications (3)

Publication Number Publication Date
JP2006521335A JP2006521335A (ja) 2006-09-21
JP2006521335A5 JP2006521335A5 (https=) 2007-03-01
JP4719144B2 true JP4719144B2 (ja) 2011-07-06

Family

ID=33099976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006505892A Expired - Fee Related JP4719144B2 (ja) 2003-03-24 2004-02-20 ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体

Country Status (14)

Country Link
US (1) US7893284B2 (https=)
EP (1) EP1608671B1 (https=)
JP (1) JP4719144B2 (https=)
AT (1) ATE454395T1 (https=)
AU (1) AU2004224053B2 (https=)
BR (1) BRPI0408703A (https=)
CA (1) CA2520142C (https=)
DE (1) DE602004024966D1 (https=)
DK (1) DK1608671T3 (https=)
EA (1) EA011123B1 (https=)
ES (1) ES2339450T3 (https=)
MX (1) MXPA05010339A (https=)
PL (1) PL378577A1 (https=)
WO (1) WO2004085459A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0113920D0 (en) 2001-06-07 2001-08-01 Sterix Ltd Composition
US8030298B2 (en) 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
WO2008090517A2 (en) * 2007-01-26 2008-07-31 Piramal Life Sciences Limited Enriched plant extract, compound, and methods for the treatment of proliferative disorders
EP2149371A1 (en) 2008-07-28 2010-02-03 PregLem S.A. Use of steroid sulfatase inhibitors for the treatment of preterm labor
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
WO2010123545A2 (en) * 2009-04-22 2010-10-28 President And Fellows Of Harvard College Angiogenesis inhibitors
WO2012116290A2 (en) * 2011-02-25 2012-08-30 Washington University Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
CN119192266A (zh) 2011-10-14 2024-12-27 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
MX365644B (es) 2012-12-18 2019-06-10 Univ Washington Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos.
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2015010054A2 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2848823T3 (es) 2013-08-23 2021-08-12 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
SG11201605178WA (en) 2013-12-24 2016-07-28 Harvard College Cortistatin analogues and syntheses and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016123056A1 (en) 2015-01-26 2016-08-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP4155314A1 (en) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
AU2017283878A1 (en) * 2016-06-15 2019-01-03 Sony Corporation Information processing device, observation system, observation method, and program
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
DE19723794A1 (de) * 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
US6288050B1 (en) * 1997-07-18 2001-09-11 Duquesne University Of The Holy Ghost Steroid sulfatase inhibitors and methods for making and using the same
GB2331987B (en) * 1997-12-04 2002-11-27 Imperial College Polycyclic sulphamate inhibitors of oestrone sulphatase
US6046186A (en) * 1997-12-24 2000-04-04 Sri International Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
ATE401896T1 (de) * 1998-06-10 2008-08-15 Sterix Ltd Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern
AU783910B2 (en) * 1999-04-30 2005-12-22 Sterix Limited Use of estrone derivatives as antitumour agents
US6953785B2 (en) * 2000-04-24 2005-10-11 Kyowa Hakko Kogyo Co., Ltd. Estra-1,3,5(10)-triene derivatives
CN100338088C (zh) * 2000-05-11 2007-09-19 医学与化学研究所 2－取代的孕－1,3,5(10)－三烯和胆－1,3,5(10)－三烯衍生物及其生物活性
GB0020498D0 (en) * 2000-08-18 2000-10-11 Sterix Ltd Compound
WO2002016395A1 (en) * 2000-08-18 2002-02-28 The Board Of Trustees Of The University Of Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv
WO2002062347A1 (en) 2001-02-05 2002-08-15 Oncology Sciences Corporation Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis
GB0421106D0 (en) * 2004-09-22 2004-10-27 Sterix Ltd Compound

Also Published As

Publication number Publication date
JP2006521335A (ja) 2006-09-21
US7893284B2 (en) 2011-02-22
US20060094696A1 (en) 2006-05-04
EP1608671A1 (en) 2005-12-28
ES2339450T3 (es) 2010-05-20
DE602004024966D1 (de) 2010-02-25
EA200501426A1 (ru) 2006-06-30
DK1608671T3 (da) 2010-05-10
CA2520142C (en) 2011-01-04
BRPI0408703A (pt) 2006-03-07
CA2520142A1 (en) 2004-10-07
EA011123B1 (ru) 2008-12-30
AU2004224053A1 (en) 2004-10-07
HK1082258A1 (en) 2006-06-02
AU2004224053B2 (en) 2011-06-09
EP1608671B1 (en) 2010-01-06
PL378577A1 (pl) 2006-05-02
MXPA05010339A (es) 2005-12-14
WO2004085459A1 (en) 2004-10-07
ATE454395T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
JP4719144B2 (ja) ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体
US6054446A (en) Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
JP5582604B2 (ja) アロマターゼインヒビターとしてのスルファメート基を含む１，２，４−トリアゾール誘導体
US8003783B2 (en) 17B-hydroxysteroid dehydrogenase inhibitors
JP4958377B2 (ja) ステロイドスルファターゼのインヒビターとしてのエストロゲン−１７−スルファメート
JP4771660B2 (ja) アロマターゼインヒビターとしてのスルファメート基を含む１，２，４−トリアゾール誘導体
JP4931312B2 (ja) ステロイドスルファターゼのインヒビターとしてのハロゲン化スルファメート−、ホスホネート−、チオホスホネート−、スルホネート−、およびスルホンアミド−化合物
JP2003519658A (ja) ステロイド構造を含む薬学的組成物およびそれらの使用
JP4553586B2 (ja) ステロイドスルファターゼを阻害するための、ステロイド化合物
CA2576614A1 (en) 2-substituted estrogen sulphamates for inhibition of steroid sulphatase
HK1082258B (en) Oestrogen derivatives as inhibitors of steroid sulphatase
CN100384868C (zh) 类固醇硫酸酯酶抑制剂的雌激素衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110217

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110310

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110401

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140408

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees